

AS

+

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

Application Number	09/701,140
Filing Date	November 21, 2000
First Named Inventor	Brian Hawtin
Group Art Unit	
Examiner Name	
Attorney Docket Number	2000-0702.ORI

Sheet	1	of	1	Attorney Docket Number	2000-0702.ORI
-------	---	----	---	------------------------	---------------

[illegible]

FOREIGN PATENT DOCUMENTS								
Examiner Initials ¹	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	TS
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
LQW	1		EP 0 189 861		Sakai	08/06/1986		
LQW			JP 9157172		Norio	06/17/1997	Abstract	
LQW			JP 9157161		Norio	06/17/1997	Abstract	
LQW	1		EP 0 208 009		Agar	01/14/1987		
LQW			GB 2 202 145B		Totten et al.	09/21/1988		
LQW	1		EP 0 424 444 B1		Boniface	05/02/1991		
LQW			GB 1 475 503		Sullivan	06/01/1977		
LQW			GB 1 537 047		Bell et al.	12/29/1978		
LQW	1		GB 1 445 437		Colgate-Palmolive	08/11/1976		

5/31/01

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**

Please type a plus sign (+) inside this box → +

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 4

Complete if Known

Application Number	09/701,140
Filing Date	November 21, 2000
First Named Inventor	Brian Hawtin
Group Art Unit	
Examiner Name	
Attorney Docket Number	2000-0702.ORI

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
LQW	1	Haider SA. Treatment of atopic eczema in children-. A clinical trial of 10% sodium cromoglycate ointment. BMJ (1977); 1570-1572.	
	2	Ariyanayagam et al (1985) Br J Dermatol 112(3), 343-348	
	3	Merck Index twelfth edition Budvari Ed (1996) excerpts relevant to documents 3 and 4.	
	4	Thirumoothy T, Greaves MW. Disodium cromoglycate ointment in atopic eczema. BMJ (1978); 500-501.	
	5	Croner S, et al. Sodium cromoglycate ointment in atopic eczema during childhood. Opuscula Medica (1981) 26(2): 49-50.	
	6	Zachariae H, Testrup-Pederson K, Thulin H, Thormann J, Herlin T, Cramers M, Jensen J, Kragballe K, Afzelius H, Overgaard Petersen H. Experimental treatment in atopic dermatitis: immunological background & preliminary results. Acta Dermatovenere (Stockholm) Suppl. (1980) 92:121-127.	
	7	Haider SA.. Treatment of atopic dermatitis in children. - Use of topical sodium cromoglycate. From The Mast Cell; Its role in Health and Disease. Eds. Pepys and Edwards (1979); Pitman Medical. 570-6	
	8	Pearce CA, Greaves MW, Plummer VM. Yamamoto S. Effect of sodium cromoglycate on antigen evoked histamine release in human skin. Clin Exp Immunol (1974) 17:437-440.	
	9	Clegg LS, Church MK, Holgate ST. Histamine secretion from human skin slices induced by anti-IgE and artificial secretagogues and the effects of sodium cromoglycate and salbutamol. Clin Allergy (1985) 15(4): 321-328	
	10	Okayama Y, Benyon RC, Rees PH, Lowman MA, Hillier K, Church MK. Inhibition profiles of sodium cromoglycate and nedocromil sodium on mediator release from mast cells of human skin, lung, tonsil, adenoid and intestine. Clin Exp Allergy (1992) 22(3): 410-409.	
LQW	11	Crossman DC, Dashwood NR Taylor GW, Wellings R, Fuller RW. Sodium cromoglycate: evidence of tachykinin antagonist activity in the human skin. J Appl Physiol (1993) 75(1): 167-172	

Examiner
Signature

Rainer Q. Wells

Date

Considered

5/31/01

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → +


PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known	
Application Number	09/701,140			
Filing Date	November 21, 2000			
First Named Inventor	Brian Hawtin			
Group Art Unit				
Examiner Name				
Attorney Docket Number	2000-0702.ORI			
Sheet	2	of	4	



OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
<div style="border-left: 2px solid black; height: 100%; position: relative;"> <div style="position: absolute; top: 0; left: -10px; transform: rotate(-90deg);"> O I P E FEB 15 2001 PATENT & TRADEMARK OFFICE </div> </div>		Walsh LJ. Ultraviolet B irradiation of skin induces mast cell degranulation and release of tumour necrosis factor. <i>Immunology and Cell Biology</i> (1995) 73: 226-233.	
		Page C. Sodium cromoglycate, a tachykinin antagonist. <i>Lancet</i> (1994) 343:70.	
		Edwards AM, Norffs AA. Cromoglycate and asthma. <i>Lancet</i> (1994) 343:426.	
		Ting S, Zweiman B, Lavker R. Cromolyn does not modulate human allergic skin reaction in vivo. <i>J Allergy Clin Immunol</i> (1983) 71(1 Pt 1): 12-17.	
		Van Bever HP, Stevens WJ. The effect of local application of disodium cromoglycate (DSCG) solution on skin prick tests. <i>J Allergy Clin Immunol</i> (1991) 1:226A.	
		Gronneberg R, Zetterstrom O. Effect of local application of disodium cromoglycate on anti-IgE induced early and late skin response in humans. <i>Clin Allergy</i> (1985) 15(2): 167-171.	
		Kimata H, Igarashi M. Inhibition of human allergic skin reactions in vivo by pretreatment with cromolyn (disodium cromoglycate). <i>Allergy</i> (1990) 45:393-395.	
		Phillips TJ, Kanj LF, Washek D, Lew R. Topical cromolyn can modify human allergic skin reactions. <i>Allergy</i> (1996) 51(3) 198-199.	
		Kjellman N-I M and Gustafsson IM. Topical sodium cromoglycate in atopic dermatitis. <i>Allergy</i> (1986) 44(6): 423-428.	
		Pike MG and Atherton DJ. Failure of a new topical sodium cromoglycate formulation to improve atopic dermatitis. <i>Eur J Ped</i> (1988) 148(2): 170.	
	Neale MG, Brown K, Hodder RW, Auty RM. The pharmacokinetics of sodium cromoglycate in man after intravenous and inhalation administration. <i>Br J Clin Pharmacol</i> (1986) 22:373-382.		

Examiner Signature	<i>Sam Q. We</i>	Date Considered	5/31/01
--------------------	------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/701,140		
		Filing Date	November 21, 2000		
		First Named Inventor	Brian Hawtin		
		Group Art Unit			
		Examiner Name			
Sheet	3	of	4	Attorney Docket Number	2000-0702.ORI

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
QW		Kimata H, Igarashi MIE. Topical cromolyn (disodium cromoglycate) solution in the treatment of young children with atopic dermatitis. Clin Exp Allergy (1990)20:281-283.	
		Kimata H, Hiratsuka S. Effect of topical sodium cromoglycate solution on atopic dermatitis: combined treatment of sodium cromoglycate solution with the oral antiallergic medication, oxatamide. Eur J Pediatr (1994)153:66-71.	
		Hiratsuka S, Yoshida A, Ishioka C, Kimata H. Enhancement of in vitro spontaneous IgE production by topical steroids in patients with atopic dermatitis. J Allergy Clin Immunol (1996)98:107-113.	
		Loh RKS, Jabara HH, Geha RS. Disodium cromoglycate inhibits Sm-Se deletional switch recombination and IgE synthesis in Human B cells. J Exp Med (1994)180(2):663-671.	
		Wu CY, Sarfati M, Heusser C, Poumeir S, Rubio-Trujillo M, Delespesse G. Glucocorticoids increase the synthesis of immunoglobulin E by interleukin-4 stimulated human lymphocytes. J Clin Invest (1991)87:870-877.	
		McHenry PM, Williams HC, Bingham EA. Management of atopic eczema. BMJ (1995)310:843-847.	
		Atopic dermatitis and cromolyn. Clin Exp Allergy (1990)20:243-244.	
		European Task Force on Atopic Dermatitis. Severity scoring of atopic dermatitis: The SCORAD index. Dermatology (1993)186:23-31.	
		Ishikura et al (1987) Drug Design & Delivery 1, 285-295.	
		Van Bever & Stevens (1989) Eur J Pediatr 149, 74.	
QW		Cox JSG et al. Disodium Cromoglycate (Intal. Advances in Drug Research) (1970); 5,115-196.	

Examiner Signature	<i>Sam QW</i>	Date Considered	5/31/01
--------------------	---------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → +

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
Sheet	4	of	4
		Application Number	09/701,140
		Filing Date	November 21, 2000
		First Named Inventor	Brian Hawtin
		Group Art Unit	
		Examiner Name	
		Attorney Docket Number	2000-0702.ORI

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Moore C et al. Topical sodium cromoglycate in the treatment of moderate to severe atopic dermatitis. Ann Allergy Asthma Immunol (1998)81, 452-458.	
		Church MK et al. Cromolyn sodium and nedocromil sodium: mast cell stabilizers, neuromodulators or anti-inflammatory drugs? In Valiner MA et al (eds), Asthma: its pathology and treatment. New York: Marcel Dekker, (1991)561-593.	
		Jackson DM et al. The effects of sodium cromoglycate on histamine aerosol-induced reflex bronchoconstriction in the anaesthetized dog. Br J Pharmac (1977)61,257-262.	
		Dixon M et al. The action of sodium cromoglycate on "C" fibre endings in the dog lung. Br J Pharmacol (1980)70,11-13.	
		Richard IM et al. Alternative modes of action of sodium cromoglycate. Agents Actions (1986)18(3/4), 294-300.	
		Collier JG et al. Evidence for an effect of sodium cromoglycate on sensory nerves in man. Br J Clin Pharmacol (1983)16,639-643.	

Examiner Signature	<i>Laura O. Wells</i>	Date Considered	5/31/01
--------------------	-----------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.